Apixaban Compared With Dalteparin in Cancer-Related Venous Thromboembolism
Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
Researchers sought to determine the relationship between body composition and pelvic fat distribution and prostate cancer aggressiveness and recurrence.
Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.
Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.
Clinically significant fatigue at baseline was identified as a predictive factor for mortality in studies of 2 forms of cancer treated with chemotherapy.
Researchers sought to determine whether patients with anemia had an increased risk of ischemic stroke and poststroke mortality.
Researchers applied a 27-gene classifier proven effective with breast, lung, and bladder cancers to predict efficacy of ICI therapy in patients with RCC.
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.